Non-Retinoid RBP4 Antagonist for Dry AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for age-related macular degeneration (AMD) due to the absence of FDA-approved therapies for the dry form, which is characterized by photoreceptor degeneration triggered by cytotoxic autofluorescent lipid-protein-retinoid aggregates in the retinal pigment epithelium, and existing compounds do not effectively lower retinal bisretinoid concentrations.
Innovation Solution
A compound, termed Compound 1, a pharmaceutically acceptable salt or ester thereof, is used to treat bisretinoid-mediated macular degeneration by lowering serum RBP4 levels and retinal concentrations of cytotoxic bisretinoids like A2E, isoA2E, and A2-DHP-PE, administered orally to inhibit the visual cycle and reduce lipofuscin accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If partial pharmacological inhibition of the visual cycle is implemented, then accumulation of cytotoxic bisretinoids is reduced, but treatment efficacy for dry AMD is insufficient with existing compounds
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of existing RBP4 antagonists to create Compound 1, which has optimized pharmacological properties. This includes changing molecular weight, lipophilicity, and binding affinity parameters to achieve superior efficacy in reducing retinal bisretinoid levels compared to prior art compounds.
Solution Approach 2:
The patent uses copying by creating a novel compound structure that replicates and improves upon the mechanism of action of existing RBP4 antagonists. Compound 1 copies the successful strategy of RBP4 inhibition but implements it through a new molecular template that avoids the limitations of previous compounds.
2Reliability
If RBP4 antagonists are used to lower serum RBP4 levels, then retinal bisretinoid concentrations decrease, but no FDA-approved therapy exists for dry AMD
Solution Approach 1:
The patent applies segmentation by dividing the drug development process into distinct phases: preclinical compound identification, in vitro validation, in vivo efficacy modeling, and toxicology assessment. Compound 1 has successfully navigated these segmented stages, with demonstrated efficacy in animal models of dry AMD, positioning it for future clinical development and potential FDA approval.
3Duration of action of stationary object
If lipofuscin accumulation is reduced through visual cycle inhibition, then photoreceptor degeneration is slowed, but no effective treatment is currently available for the slowly progressing neurodegenerative disorder
Solution Approach 1:
The patent applies preliminary action by implementing a preventive therapeutic strategy that slows the progression of dry AMD before irreversible photoreceptor loss occurs. Compound 1 acts early in the disease pathway by inhibiting bisretinoid formation at its source, thereby preventing subsequent photoreceptor degeneration and extending the functional lifespan of the retina in atrophic AMD.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 demonstrates a significant reduction in serum RBP4 levels and retinal bisretinoids, potentially delaying or preventing vision loss in AMD and Stargardt Disease, offering a preclinical efficacy model for dry AMD treatment.
Implementation Method 1
RBP4 is a plasma protein that binds retinol with high affinity and transports it to various tissues
Implementation Method 2
A1120 antagonizes the interaction of RBP4 and TTR, lowering the concentration of both proteins in the blood
Implementation Method 3
RBP4 tagged with a donor or acceptor fluorophore with TTR tagged with a donor or acceptor fluorophore
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method for treating bisretinoid-mediated macular degeneration in a mammal afflicted therewith comprising administering to the mammal an effective amount of a compound having the structure: (I), or an ester or a pharmaceutically acceptable salt thereof.